Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA

Despite facing one-year delay, Coherus is buoyed by FDA’s apparent support for its decision not to conduct clinical study in cancer patients; agency requests company develop more sensitive immunogenicity assay and reanalyze subset of samples from study conducted in healthy subjects.